GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Liabilities-to-Assets

MorphoSys AG (XSWX:MOR) Liabilities-to-Assets : 0.98 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is MorphoSys AG Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. MorphoSys AG's Total Liabilities for the quarter that ended in Dec. 2023 was CHF1,864.7 Mil. MorphoSys AG's Total Assets for the quarter that ended in Dec. 2023 was CHF1,911.0 Mil. Therefore, MorphoSys AG's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.98.


MorphoSys AG Liabilities-to-Assets Historical Data

The historical data trend for MorphoSys AG's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Liabilities-to-Assets Chart

MorphoSys AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.63 0.90 0.93 0.98

MorphoSys AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.96 0.99 - 0.98

Competitive Comparison of MorphoSys AG's Liabilities-to-Assets

For the Biotechnology subindustry, MorphoSys AG's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MorphoSys AG's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Liabilities-to-Assets falls into.



MorphoSys AG Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

MorphoSys AG's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=1864.707/1910.964
=0.98

MorphoSys AG's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=1864.707/1910.964
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MorphoSys AG  (XSWX:MOR) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


MorphoSys AG Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


MorphoSys AG (XSWX:MOR) Business Description

Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

MorphoSys AG (XSWX:MOR) Headlines

From GuruFocus